Molecular targets for the prevention and/or treatment of fibrosis, hypertrophic scars or keloids

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9840704
SERIAL NO

14909626

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to a therapeutic compound comprising: an agent that inhibits the activity of at least one gene selected from the group consisting of HIC1, FOXS1, CREB5, IRF7, POU2F2, STAT4, TCF4, and/or an agent that enhances the activity of at least one gene selected from the group consisting of MAF, MEOX2, SIX2.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
URGO RECHERCHE INNOVATION ET DEVELOPPEMENT21300 CHENÔVE

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Darzacq, Xavier Antony, FR 6 0
Dugast-Darzacq, Claire Antony, FR 4 0
Noizet, Maite Versailles, FR 4 0

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jun 12, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 12, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00